Loading...
•
Sep 30, 2020
Celldex Q3 2020 Earnings Report
Celldex reported third quarter results with focus on advancing clinical programs and expanding development opportunities for CDX-0159.
Key Takeaways
Celldex Therapeutics reported $0.7 million in revenue for the third quarter of 2020. The company's cash position remains strong with $199.6 million in cash, cash equivalents, and marketable securities. Celldex believes its current cash reserves are sufficient to fund operations through 2023.
Initiated two Phase 1b studies for CDX-0159 in chronic urticaria.
Advanced CDX-527, a bispecific program candidate, into clinical trials for solid tumors.
Expanded the CDX-1140 program with a combination cohort in pancreatic cancer.
Prioritizing opportunities to expand development of CDX-0159 into additional therapeutic areas.
Forward Guidance
Celldex believes that the cash, cash equivalents and marketable securities at September 30, 2020 are sufficient to meet estimated working capital requirements and fund planned operations through 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...